The following table provides supplemental pro forma information: | ||||
Unaudited Pro Forma Consolidated Results(a) | ||||
Year Ended December 31, | ||||
(MILLIONS OF DOLLARS, EXCEPT PER SHARE DATA) | 2011 | |||
Revenues | $ | 61,122 | ||
Net income attributable to Pfizer Inc. | 10,228 | |||
Diluted earnings per share attributable to Pfizer Inc. common shareholders | 1.30 | |||
(a) | The pro forma information for December 31, 2011 assumes that the acquisition of King occurred on January 1, 2010. |